[medik8]

IVAX Launches Gabapentin Capsules

MIAMI--(BUSINESS WIRE)--Mar 23, 2005 - IVAX Corporation (AMEX:IVX) (LSE:IVX.L) (WSE:IVX) launched its AB-rated gabapentin capsules in 100 mg, 300 mg and 400 mg dosage strengths. Gabapentin is the generic equivalent of Neurontin a drug used to treat epileptic seizures which is marketed by Warner-Lambert, a unit of Pfizer Inc. According to IMS data, for the fourth quarter 2004, U.S. sales of Neurontin and gabapentin in 100, 300 and 400 mg dosage strengths were $337 million.

On February 11, 2005, IVAX entered into a settlement of litigation with the United States Food and Drug Administration and Alpharma Inc. regarding gabapentin. Pursuant to the settlement, Alpharma waived its FDA awarded 180-day exclusivity in favor of IVAX, effective on March 23, 2005 for gabapentin capsules, and April 29, 2005 for gabapentin tablets. As a result, IVAX can market AB rated gabapentin capsules and tablets prior to the expiration of Alpharma's 180-day marketing exclusivity periods.

On August 18, 2004, IVAX launched its non-AB rated gabapentin tablets in 100, 300, and 400 mg dosage strengths. IVAX will continue to market its non-AB rated tablets as well as its AB rated capsules in 100, 300, and 400 mg dosage strengths through its subsidiary, IVAX Pharmaceuticals, Inc.

IVAX is presently litigating whether its gabapentin products infringe a patent held by Pfizer. A trial in the U.S., District Court of New Jersey has not yet been scheduled.

IVAX Corporation, headquartered in Miami, Florida, discovers, develops, manufactures, and markets branded and brand equivalent (generic) pharmaceuticals and veterinary products in the U.S. and internationally.

Copies of this and other news releases may be obtained free of charge from IVAX' website at ivax.com.